Acesso livre
Acesso livre

Ginecologia Geral

[Comunicado de imprensa – ainda não publicado] Estudo randomizado | Abordagem minimamente invasiva para histerectomia no câncer de colo do útero está associada à pior sobrevida livre de doença do que a cirurgia aberta.

25 Mar, 2022 | 14:49h

Minimally Invasive Approach to Hysterectomy in Cervical Cancer Associated with Poorer Disease-Free Survival Than Open Surgery – Society of Gynecologic Oncology


Estudo multicêntrico de coorte retrospectiva | Desfechos e segurança do rastreamento baseado no histórico para aborto medicamentoso.

23 Mar, 2022 | 11:32h

Outcomes and Safety of History-Based Screening for Medication Abortion: A Retrospective Multicenter Cohort Study – JAMA Internal Medicine

Comentário convidado: It Is Time to Change the Standard of Medication Abortion – JAMA Internal Medicine (gratuito por tempo limitado)


M-A | Risco de carcinomatose peritoneal após redução do risco por salpingo-ooforectomia em portadoras da variante patogênica BRCA1/2.

23 Mar, 2022 | 11:24h

Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis – Journal of Clinical Oncology


Plano de cuidado multidisciplinar do câncer de ovário em pacientes idosos.

21 Mar, 2022 | 15:59h

Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statement—A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO – Cancers


Tendências de tumores associados ao HPV, características demográficas e vacinação nos EUA, 2001-2017.

17 Mar, 2022 | 12:46h

Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017 – JAMA Network Open

Entrevista com o autor: Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations

Conteúdos relacionados:

[Not published yet] Single-dose HPV vaccine highly effective, researchers say – “Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide”.

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs


Revisão sistemática | Programas perioperatórios de recuperação melhorada (enhanced recovery after surgery) para mulheres com câncer ginecológico.

16 Mar, 2022 | 17:50h

Perioperative enhanced recovery programmes for women with gynaecological cancers – Cochrane Library

Ver também: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines (algumas diretrizes têm acesso gratuito)


Atualização da diretriz ASCO de recomendações estratificadas por disponibilidade de recursos | Tratamento de cuidado de pacientes com câncer de colo do útero invasivo.

14 Mar, 2022 | 13:22h

Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update – JCO Global Oncology

Comunicado de imprensa: ASCO Guideline Recommends Addition of Monoclonal Antibody to Invasive Cervical Cancer Management – ASCO Daily News


Estudo randomizado | Metenamina hipurato (um tratamento preventivo não antibiótico) é não inferior a antibióticos profiláticos para tratar infecções recorrentes de trato urinário em mulheres.

11 Mar, 2022 | 15:19h

Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial – The BMJ

Comunicado de imprensa: Antiseptic drug as good as antibiotics for preventing recurrent urinary tract infections – BMJ Newsroom

Editorial: Methenamine hippurate for recurrent urinary tract infections – The BMJ

Comentários:

Trial supports antibiotic alternative for recurrent urinary infections – CIDRAP

Nonantibiotic Prophylaxis Noninferior for Recurrent UTI – HealthDay

 

Comentário no Twitter

 


Riscos de outros tipos de câncer, além dos cânceres de mama e de ovário, associados às variantes patogênicas BRCA1 e BRCA2.

3 Mar, 2022 | 15:45h

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants – Journal of Clinical Oncology

Comentário: Faulty BRCA genes linked to prostate and pancreatic cancers – University of Cambridge


Diretriz atualizada | Momento da cirurgia eletiva e avaliação de risco após infecção por SARS-CoV-2 – “Mantemos a orientação de que os pacientes devem evitar cirurgias eletivas dentro de 7 semanas da infecção, a menos que os benefícios superem o risco de aguardar por tal período.”

1 Mar, 2022 | 15:38h

Timing of elective surgery and risk assessment after SARS-CoV-2 infection: an update – Anaesthesia

Conteúdos relacionados:

Perioperative cardiovascular considerations prior to elective noncardiac surgery in patients with a history of Covid-19.

Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

BJS commission on surgery and perioperative care post-COVID-19.

The risk of postoperative complications following major elective surgery in active or resolved COVID-19 in the United States – Major, elective surgery 0–4 weeks after Covid-19 is associated with greatly increased risk of postoperative complications; surgery performed 4–8 weeks after infection is still associated with an increased risk of pneumonia.

ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.

Position statement: Perioperative management of post-COVID-19 surgical patients.

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.